Intermediate alleles and reduced penetrance – the genetic 'gray area' of Huntington’s disease, explained
Dimebon fails to improve symptoms in HD patients in the HORIZON trial
Bad news for Huntexil – the FDA requires another trial before it can be approved in the US
Success for brain ‘gene therapy’ in Parkinson’s disease – good news for similar treatments being developed in HD
Is gene silencing as exciting as it sounds for HD, and what might the future hold?
HDBuzz interviews Graeme Bilbe, Global Head for Neuroscience at pharmaceutical giant Novartis, about their HD researc
How smart are sheep, and why do HD researchers care?
HDBuzz interviews three top scientists from CHDI, the biggest funder and driver of HD research worldwide
Day 3 of CHDI’s HD therapeutics conference: growth factors and CHDI’s advanced therapies
Day 2 of CHDI’s HD therapeutics conference: figuring out energy problems in HD
Day 1 of CHDI’s HD therapeutics conference: exploring abnormal brain connections and silencing the HD gene